This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of pancreas췌장의 악성신생물 (췌장암)

📋 Contents and key points
A.Classification code — C25 (malignant neoplasm of pancreas)
B.Synonyms — pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), pancreatic head cancer, pancreatic body/tail cancer, pancreatic neuroendocrine tumor
C.Adult onset — very high (mainly in the 60s–70s; rare before age 40)
1.History — history of recognition of pancreatic cancer; Whipple operation (1935); development of chemotherapy such as FOLFIRINOX
2.Causes — smoking (the most established risk factor), type 2 diabetes, obesity, chronic pancreatitis, heavy drinking, occupational exposure
3.Genetics — KRAS (~90%), SMAD4 (~55%), CDKN2A (~30%), TP53 (~70%); hereditary: BRCA1/2, Lynch, Peutz-Jeghers
4.Epidemiology — 12th most common cancer and 7th leading cause of cancer death worldwide; 8,000–9,000 cases per year in Korea; incidence increasing
5.Pathophysiology — multistep carcinogenesis PanIN-1→PanIN-2→PanIN-3→PDAC; early KRAS mutation and late SMAD4 loss
6.Symptoms — painless jaundice (head cancer), epigastric and back pain, weight loss, indigestion, new-onset diabetes
7.Signs — Courvoisier gallbladder, jaundice, Courvoisier sign, elevated CA19-9, Trousseau sign
8.Screening — no standard screening test; MRI/EUS for hereditary high-risk groups; surveillance programs for BRCA carriers
9.Diagnosis — CT (dynamic triphasic), MRI/MRCP, EUS-FNA; CA19-9; AJCC TNM 8th edition; pancreatoscopy
10.Treatment — Whipple, distal pancreatectomy; FOLFIRINOX, gemcitabine+nab-paclitaxel; olaparib (BRCA); NALIRIFOX
11.Prognosis — overall 5-year survival about 12%; about 25–30% after resection; median OS about 11 months in metastatic disease
12.Prevention — smoking cessation (most important), management of obesity and diabetes, moderate drinking, early management of chronic pancreatitis, genetic testing
13.References — 10 items including NCCN pancreatic cancer, PRODIGE 4/ACCORD 11, MPACT, POLO and NALIRIFOX studies

Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date


A. Classification codes

CategoryDetails
ICD-10 codeC25 — Malignant neoplasm of pancreas
SubcodesC25.0 head of pancreas, C25.1 body of pancreas, C25.2 tail of pancreas, C25.3 pancreatic duct, C25.4 endocrine pancreas (islet cells), C25.7 other parts, C25.8 overlapping lesion of pancreas, C25.9 unspecified
Special Copayment Reduction codeV193
Main histological typesPancreatic ductal adenocarcinoma (PDAC) about 85–90%; acinar cell carcinoma, cancer associated with intraductal papillary mucinous neoplasm (IPMN), pancreatic neuroendocrine tumor (pNET; C25.4), solid pseudopapillary neoplasm (SPN)

B. Synonyms

Pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC), pancreatic head cancer, pancreatic body/tail cancer, pancreatic adenocarcinoma, pancreatic cancer, carcinoma of the pancreas. Pancreatic neuroendocrine tumor (pNET) is a clinically distinct entity but is classified as C25.4. In Korea, 'pancreatic cancer' usually refers to PDAC.

C. Adult onset

Pancreatic cancer (PDAC) is a disease with a very high frequency of adult onset, with a median age at diagnosis of about 70 years. Occurrence before age 40 is rare, at less than 1–2% of the total, and is mostly related to hereditary predisposition. Hereditary pancreatic cancer (BRCA2, Lynch syndrome, Peutz-Jeghers syndrome, etc.) tends to occur at somewhat younger ages. Pancreatic neuroendocrine tumors (pNET) occur across a relatively wide age range.


1. History

The most important milestone in the history of pancreatic cancer is the pancreaticoduodenectomy reported by Allen Oldfather Whipple in 1935. The so-called Whipple procedure has remained the standard curative operation for cancer of the pancreatic head for the following 90 years. Operative mortality initially reached 30–50%, but has fallen to less than 3% in modern specialized centers.

Historically, pancreatic cancer was difficult to diagnose and had a poor prognosis, and for a long time there was no effective treatment. Gemcitabine became the standard first-line agent for pancreatic cancer after demonstrating superior clinical benefit over 5-FU in a 1997 study preceding CONKO-001, and was subsequently established by the randomized study of Burris et al. in 2003. In 2011, the PRODIGE 4/ACCORD 11 trial showed that FOLFIRINOX (oxaliplatin + irinotecan + leucovorin + 5-FU) combination therapy markedly prolonged median OS compared with gemcitabine alone in metastatic pancreatic cancer (11.1 vs 6.8 months), causing a major stir in the global oncology community. In 2013, the MPACT trial showed that gemcitabine + nab-paclitaxel (albumin-bound paclitaxel) improved OS compared with gemcitabine alone, adding another standard first-line treatment option.

As the clinical significance of BRCA1/2 mutations in hereditary pancreatic cancer came to the fore, the 2019 POLO trial showed that olaparib (a PARP inhibitor) maintenance therapy significantly prolonged PFS to 7.4 months (vs 3.8 months in the placebo group) in patients with gBRCA1/2-mutated metastatic pancreatic cancer, leading to FDA approval. In 2023–2024, the NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU + leucovorin) trial and clinical trials of next-generation KRAS G12C and G12D inhibitors are under way, and treatment continues to advance.

2. Causes

Smoking

Smoking is the best-established risk factor for pancreatic cancer; smokers have about twice the risk of nonsmokers. After smoking cessation the risk gradually decreases, approaching that of nonsmokers after 15–20 years. Carcinogens in tobacco such as N-nitrosamines and PAHs (polycyclic aromatic hydrocarbons) act on the pancreas.

Diabetes and obesity

Type 2 diabetes may be both a risk factor for and an early symptom of pancreatic cancer (bidirectional association). Long-standing diabetes (10 years or more) increases the risk about 1.8–2-fold, while pancreatic cancer itself can cause new diabetes (new-onset diabetes). Obesity (BMI ≥30) increases pancreatic cancer risk about 1.3–1.5-fold, with abdominal fat accumulation and insulin resistance contributing.

Chronic pancreatitis and others

Chronic pancreatitis increases pancreatic cancer risk about 2–15-fold, and the risk is even higher in hereditary chronic pancreatitis (PRSS1, SPINK1 mutations). Excessive alcohol consumption raises the risk indirectly through chronic pancreatitis. Associations have also been reported with occupational chemical exposure (dry-cleaning solvents, chlorinated hydrocarbons) and asbestos exposure.

3. Genetics

The molecular genetics of pancreatic cancer (PDAC) is characterized by mutations in four key driver genes. KRAS (about 90%): the most frequent oncogene mutation; G12D (about 40%), G12V (about 30%) and G12R (about 15%) mutations are common. KRAS is the earliest event in PDAC development and is observed from the PanIN-1 stage. CDKN2A (p16/INK4A) (about 30–40%): loss of the p16 protein leaves the CDK4/6–cyclin D complex constitutively active, so passage through the G1→S cell cycle is uncontrolled. SMAD4 (DPC4) (about 50–55%): a downstream effector of the TGF-β signaling pathway; loss of SMAD4 blocks the tumor-suppressive effect of TGF-β. SMAD4 loss is associated with distant metastasis and also affects the response to systemic therapy (FOLFIRINOX). TP53 (about 70%): mutations accumulate at the late PanIN stage and suppress the DNA damage response and apoptosis.

Hereditary pancreatic cancer: about 5–10% of all PDAC is associated with a hereditary predisposition. Pancreatic cancer risk is high in carriers of BRCA2 mutations (about 5–10%), BRCA1 mutations, ATM mutations and PALB2 mutations. Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations) increases pancreatic cancer risk about 4-fold, and MSI-H tumors are sensitive to immunotherapy. In Peutz-Jeghers syndrome (STK11/LKB1 mutations), the lifetime risk of pancreatic cancer reaches 30–40%. Germline CDKN2A mutations (familial atypical multiple mole melanoma syndrome, FAMMM) also carry a high pancreatic cancer risk. BRCA2-mutated PDAC is clinically important because it responds to PARP inhibitor (olaparib) therapy.

4. General epidemiology

Worldwide, pancreatic cancer ranks 12th in incidence and 7th in cancer mortality, but because of its extremely poor prognosis it is predicted to become the second leading cause of cancer death in Western countries by around 2030. There are about 500,000 new cases worldwide each year (GLOBOCAN 2020). Incidence is high in Europe, North America and Japan and low in Africa. In Korea, about 8,000–9,000 new cases occur each year, and the 5-year survival rate is about 12%, making it one of the cancers with the worst prognosis.

In Korea, the incidence of pancreatic cancer has been rising steadily over the past 10–20 years, mainly against a background of growing obese and diabetic populations and population aging. By sex, it is slightly more common in men than in women, but the difference in sex ratio is small. The stage distribution at diagnosis is localized (stage I–II) about 15–20%, locally advanced (stage III) about 30%, and distant metastasis (stage IV) about 50–55%, so most cases are at an advanced stage at diagnosis. This is because there are no early symptoms and there is currently no standard screening test.

5. Pathophysiology

The pathogenesis of PDAC is understood as a multistep carcinogenesis model in which a precursor lesion, pancreatic intraepithelial neoplasia (PanIN), progresses to invasive cancer. PanIN is classified by histologic grade into PanIN-1 (low-grade dysplasia), PanIN-2 (moderate dysplasia) and PanIN-3 (high-grade dysplasia, equivalent to carcinoma in situ).

Order of molecular events: KRAS mutation is present at almost every stage from PanIN-1, and spontaneous PDAC development has been confirmed in KRAS G12D mutant mouse models, so it functions as the initiator of carcinogenesis. CDKN2A loss appears at PanIN-2 and promotes cell-cycle progression. SMAD4 loss occurs at the transition from PanIN-3 to invasive cancer and increases the tendency to metastasize. TP53 mutations accumulate in late PanIN/invasive cancer. PDAC is characterized by abundant desmoplastic stroma, which acts as a barrier to drug penetration and forms an immunosuppressive microenvironment. Cancer-associated fibroblasts (CAFs), regulatory T cells (Tregs) and MDSCs promote immune evasion.

6. Symptoms

Cancer of the pancreatic head

The most characteristic symptom of pancreatic head cancer is painless jaundice, caused by obstruction of the common bile duct. It is accompanied by progressive jaundice, pruritus, dark urine and pale stools. Indigestion, steatorrhea and weight loss are common, and new diabetes with poor glycemic control may develop. Back or epigastric pain worsens when the tumor invades the celiac plexus and tends to be worse at night.

Cancer of the pancreatic body and tail

Cancer of the body and tail rarely causes jaundice, and symptoms appear later. The main symptoms are epigastric and left upper quadrant pain, weight loss and loss of appetite, and the disease is often already locally advanced or metastatic at diagnosis. Splenomegaly due to splenic vein thrombosis and bleeding from gastric varices also occur rarely.

7. Signs

On physical examination, jaundice (yellow discoloration of the skin and sclera) may be accompanied by Courvoisier's gallbladder (a palpable, nontender gallbladder). This is a sign of malignant obstruction around the bile duct (usually pancreatic head cancer or distal cholangiocarcinoma). Abdominal examination may reveal epigastric tenderness and, rarely, a palpable abdominal mass. In advanced cancer, Virchow's node (left supraclavicular lymphadenopathy), Sister Mary Joseph nodule (umbilical metastasis) and Trousseau's sign (migratory thrombophlebitis with coagulopathy) may also be observed. Serum CA19-9 is a useful tumor marker for monitoring treatment response and recurrence in pancreatic cancer (sensitivity about 80%, specificity about 80%), but it is not produced in people with the Lewis (a-b-) blood type, so false negatives are possible.

8. Screening

There is currently no national standard screening test for pancreatic cancer in the general population. The low prevalence of pancreatic cancer and the false positives of imaging screening limit this. However, screening programs are recommended for the following high-risk groups: ① gBRCA1/2 mutation carriers with a family history of pancreatic cancer in one or more relatives, ② gPALB2 or gATM mutations + family history of pancreatic cancer, ③ Lynch syndrome + family history of pancreatic cancer, ④ Peutz-Jeghers syndrome, ⑤ familial pancreatic cancer (pancreatic cancer in two or more first-degree relatives), ⑥ germline CDKN2A mutations. In these groups, annual screening with EUS (endoscopic ultrasound) or MRI/MRCP is recommended (CAPS Consortium guidelines). Smoking cessation, obesity management and diabetes treatment contribute to primary prevention.

9. Diagnosis

Imaging

Dynamic CT (pancreatic-protocol triphasic CT) is the most important first-line test for evaluating tumor location, size, vascular invasion and distant metastasis. Pancreatic cancer is hypovascular and appears hypoattenuating in the arterial phase. MRI/MRCP is used as a complement for evaluating liver metastases, small lesions and IPMN. EUS (endoscopic ultrasound) is excellent for detecting small lesions of 2 cm or less and for obtaining tissue by EUS-FNA. PET-CT is used to evaluate distant metastasis and to differentiate indeterminate metastatic lesions.

Tissue diagnosis and staging

Resectable lesions are sometimes operated on without preoperative tissue confirmation, but for lesions that are candidates for systemic therapy or are borderline resectable, tissue is confirmed by EUS-FNA or CT-guided percutaneous biopsy. AJCC TNM 8th edition: T1 (2 cm or less), T2 (2–4 cm), T3 (more than 4 cm or invasion of the duodenum/bile duct), T4 (invasion of the celiac axis or superior mesenteric artery); N1 (1–3 lymph nodes), N2 (4 or more); M1. Resectability classification: resectable, borderline resectable, locally advanced (unresectable), metastatic. Systematic molecular profiling (NGS panel) is used to determine KRAS mutation, SMAD4 status, BRCA1/2, NTRK fusion, MSI and others.

Pancreatoscopy

Peroral pancreatoscopy is a technique for directly visualizing and biopsying the inside of the main pancreatic duct, and is used to assess whether an IPMN is malignant and for precise diagnosis of main-duct IPMN.

10. Treatment

Surgical treatment

Pancreaticoduodenectomy (Whipple operation) removes en bloc the pancreatic head, distal common bile duct, duodenum, gallbladder and gastric pylorus (pylorus-preserving Whipple), and is the standard operation for resectable cancer of the pancreatic head and neck. Distal pancreatectomy is performed for cancer of the pancreatic body and tail, often with simultaneous splenectomy. Total pancreatectomy is considered for multifocal lesions or when recurrence at the resection margin is a concern. Postoperative adjuvant chemotherapy (gemcitabine + capecitabine, FOLFIRINOX, or gemcitabine alone) is recommended.

Systemic therapy

The standard first-line treatment for metastatic pancreatic cancer is FOLFIRINOX (oxaliplatin 85 mg/m² + irinotecan 180 mg/m² + leucovorin 400 mg/m² + 5-FU 400 mg/m² bolus + 5-FU 2,400 mg/m² as a 46-hour continuous infusion; PRODIGE 4/ACCORD 11, median OS 11.1 vs 6.8 months) or gemcitabine + nab-paclitaxel (MPACT, median OS 8.5 vs 6.7 months). FOLFIRINOX is used for patients with good performance status (ECOG PS 0–1), and gemcitabine + nab-paclitaxel or gemcitabine alone for those with poor performance status. In 2024, the NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU + leucovorin) trial reported improved OS compared with gemcitabine + nab-paclitaxel. Patients with gBRCA1/2 mutations: olaparib maintenance therapy when disease is controlled after platinum-based first-line treatment (POLO trial, PFS 7.4 vs 3.8 months). Pembrolizumab can be used in MSI-H pancreatic cancer. KRAS G12C inhibitors (sotorasib, adagrasib) are being studied in G12C-mutated PDAC, and G12D inhibitors are also in clinical development.

11. Prognosis

With an overall 5-year survival rate of about 11–12%, pancreatic cancer is one of the solid cancers with the worst prognosis. 5-year survival by stage: stage IA (T1N0M0): about 40–50%; stage IIA (T3N0M0): about 20–25%; stage IIB (N1M0): about 10–15%; stage III (T4 or N2): about 3–5%; stage IV (distant metastasis): 5-year survival less than about 3%, median OS about 6–11 months (depending on treatment). The 5-year survival rate after curative resection (R0) is about 25–30%, but about 80% recur even after resection. Poor prognostic factors: vascular invasion (portal vein, mesenteric vessels), lymph node metastasis, positive resection margin (R1), high baseline CA19-9, SMAD4 loss. Relatively favorable prognostic factors: MSI-H, BRCA2 mutation (sensitivity to platinum therapy), NTRK fusion.

12. Prevention

Smoking cessation: the most effective lifestyle change for reducing pancreatic cancer risk; the risk gradually decreases after quitting. Management of obesity and diabetes: lower insulin resistance by maintaining an appropriate weight, exercising regularly and treating diabetes. Limiting alcohol: prevention of chronic pancreatitis due to heavy drinking. Early management of chronic pancreatitis: appropriate treatment of recurrent acute pancreatitis and removal of risk factors. Management of hereditary high-risk groups: regular EUS/MRI surveillance and genetic counseling for carriers of identified high-risk gene mutations such as BRCA1/2, PALB2, ATM, Lynch syndrome and Peutz-Jeghers syndrome. Limiting intake of red and processed meat and increasing intake of vegetables and fruit are also recommended.


13. References

  1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. Version 2.2025. Fort Washington, PA: NCCN; 2025.
  2. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer (PRODIGE 4/ACCORD 11). N Engl J Med. 2011;364(19):1817-1825.
  3. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine (MPACT). N Engl J Med. 2013;369(18):1691-1703.
  4. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO). N Engl J Med. 2019;381(4):317-327.
  5. Wainberg ZA, Melisi D, Macarulla T, et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma. Lancet. 2023;402(10409):1272-1281.
  6. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol. 2010;7(3):163-172.
  7. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47-52.
  8. Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339-347.
  9. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801-1806.
  10. Korean Pancreatic Cancer Study Group. Clinical practice recommendations for pancreatic cancer (2023 revision). Seoul: Korean Academy of Medical Sciences; 2023.